This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life.
Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to 10 countries in Western Europe. Subjects will be block-randomized equally to each of the manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis in visible locations). If subjects present with multiple manifestations, they will be allocated to the manifestation which is most severe, as determined by the subject.
However, all manifestations will be assessed for efficacy at each study visit.
|Treatment||Placebo, Apremilast (CC-10004)|
|Clinical Study Identifier||NCT03774875|
|Last Modified on||25 October 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.